Renal disease News and Research

RSS

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

New program may help reduce hospital readmission rates for high-risk seniors

SCAN Health Plan and Lakewood IPA have partnered with Dovetail Health in a program designed to reduce readmission rates for high-risk seniors following discharge from hospitals and skilled nursing facilities.

4 Jan 2011

American Regent initiates voluntary recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%

American Regent is conducting a nationwide voluntary recall to the consumer and user level of ALL unexpired lots of the following products: Sodium Bicarbonate Injection, USP, 7.5%, 44.6 mEq/50 mL, Single Dose Vial

24 Dec 2010

Davita launches online tool for dialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease and end stage renal disease, today announced the launch of MyDaVita, an online tool intended to help patients connect with one another for friendship, support and educational information.

15 Dec 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab- Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

9 Dec 2010

Type 2 diabetics who consume alcohol at increased risk for blurry vision

A new study published in the journal Diabetic Medicine reveals that among patients with type 2 diabetes, alcohol consumption was associated with an increased risk of deterioration of visual acuity.

2 Dec 2010

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc. today announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

30 Nov 2010

New review from JASN highlights hazards of fructose

More and more people have become aware of the dangers of excessive fructose in diet. A new review on fructose in an upcoming issue of the Journal of the American Society of Nephrology (JASN) indicates just how dangerous this simple sugar may be.

30 Nov 2010

FG-2216 drug offers new treatment option for kidney disease-related anemia

A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients—possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

30 Nov 2010

DaVita announces emergency preparedness information for dialysis patients during winter season

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD) and end stage renal disease (ESRD), announced today important emergency preparedness information for dialysis patients during the upcoming winter season.

23 Nov 2010

Dangers of excess fructose

23 Nov 2010

DaVita announces meal planning tool for dialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease (ESRD) and chronic kidney disease (CKD), offers patients with very restricted diets an easy to use meal planning tool and recipes for their favorite Thanksgiving dinners at DaVita.com.

22 Nov 2010

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.

22 Nov 2010

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

On November 20 at the American Society of Nephrology 43rd Annual Meeting, Columbia University Assistant Professor of Clinical Medicine Andrew Bomback, MD, presented results from a patient case series assessing the potential therapeutic value of H.P. Acthar Gel (repository corticotropin injection) as a treatment for patients with nephrotic syndrome, a kidney disorder characterized by excessive loss of urinary protein.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Study finds common gene variant in African Americans increases risk of kidney disease

In African Americans with kidney disease related to hypertension (high blood pressure), a common gene variant is associated with a sharply increased risk of progressive kidney disease, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition. End Stage Renal Disease (ESRD) associated with hypertension occurs in the African American population at a rate 13.1 times greater than that of their white counterparts.

22 Nov 2010

Nephrologist’s care reduces ESRD development during first year of dialysis: Study

Among kidney disease patients, earlier care from a nephrologist is associated with a decreased likelihood of developing end-stage renal disease and a lower risk of death during the first year of dialysis, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

20 Nov 2010

Early nephrology care associated with lower mortality and incidence of end stage renal disease

Earlier care from a nephrologist reduces the chance of kidney patients developing end-stage renal disease and lowers their risk of death during the first year of dialysis, according to a study by the University of Michigan Kidney Epidemiology & Cost Center.

20 Nov 2010

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that the Company will present new data at the American Society of Nephrology meeting being held in Denver, Colorado, on its late-stage investigational drug Soluble Ferric Pyrophosphate, which is being studied for the treatment of iron-deficiency anemia in ESRD patients.

20 Nov 2010

Study highlights poor outcomes for patients with ESRD admitted over weekend

Patients with end-stage renal disease who are admitted to the hospital during the weekend are at increased risk of death, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

20 Nov 2010

Renal disease News and Research

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

New program may help reduce hospital readmission rates for high-risk seniors

American Regent initiates voluntary recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%

Davita launches online tool for dialysis patients

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

Type 2 diabetics who consume alcohol at increased risk for blurry vision

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

New review from JASN highlights hazards of fructose

FG-2216 drug offers new treatment option for kidney disease-related anemia

DaVita announces emergency preparedness information for dialysis patients during winter season

Dangers of excess fructose

DaVita announces meal planning tool for dialysis patients

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

VYTORIN reduces major vascular events in patients with chronic kidney disease

Study finds common gene variant in African Americans increases risk of kidney disease

Nephrologist’s care reduces ESRD development during first year of dialysis: Study

Early nephrology care associated with lower mortality and incidence of end stage renal disease

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Study highlights poor outcomes for patients with ESRD admitted over weekend

Free guide - Everything about renal proximal tubule cells eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News